Tuesday, April 12, 2016

BRIEF-Actinium says phase 3 Sierra trial of Iomab-B is expected to enroll 150 patients

* UPDATE - Actinium announces selection of Zevacor Pharma,

Inc. For clinical production and supply of Iomab-B for pivotal

Phase 3 Sierra trial

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)